Meta-analysis for the efficacy and safety of Hanchuan Zupa Granule in treating bronchial asthma

Objective:To systematically evaluate the clinical efficacy and safety of Hanchuan Zupa granule(HCZPG)in the treatment of bronchial asthma.Methods:The Cochrane Library,Pubmed,EMBASE,CNKI,CBM,VIP and Wanfang were searched up to June 2021.Randomized controlled trials,which assessed the effects of HCZPG in the treatment of bronchial asthma,were included in this review,and the references included in the selected studies were also tracked.The methodological quality of eligible studies were assessed by the Cochrane Collaboration’s tool.Data of the included studies were extracted independently by two authors and meta-analysis was conducted using RevMan5.3.Results:A total of 97 relevant literatures were retrieved,and 13 studies were finally included,involving 1189 patients.The aggregated meta-analysis results indicated that HCZPG improved total clinical efficacy[RR=1.18,95%CI(1.13,1.24),P<0.00001],FEV1(L)[WMD=0.48,95%CI(0.22,0.74),P=0.0003],FVC(L)[WMD=1.23,95%CI(0.5,1.96),P=0.001],FEV1/FVC(%)[WMD=7.37,95%CI(5.91,8.84),P<0.00001],PEF[SMD=1.19,95%CI(0.82,1.56),P<0.00001],IL-4[WMD=-12.13,95%CI(-16.36,-7.90),P<0.00001],IL-6[WMD=-29.55,95%CI(-40.71,-18.39),P<0.00001],TNF-α[SMD=-2.73,95%CI(-3.57,-1.88),P<0.00001],PaO2[WMD=8.97,95%CI(6.09,11.85),P<0.00001],but the risk of adverse events were not statistically significant between the two groups[RR=0.68,95%CI(0.39,1.18),P=0.17].Conclusion:HCZPG shows good clinical curative effects in treating bronchial asthma without increasing the incidence of adverse events.

寒喘祖帕颗粒治疗支气管哮喘疗效及安全性meta分析

目的:系统评价寒喘祖帕颗粒治疗支气管哮喘的临床疗效及安全性。方法:计算机检索Cochrane Library、PubMed、EMBASE、中国学术期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM),维普中文科技期刊数据库(VIP)和万方数字资源库(Wangfang),检索时间限定为建库至2021年6月,检索所有寒喘祖帕颗粒治疗支气管哮喘的随机对照试验(randomized control trials,RCTs),并追踪纳入研究的参考文献。由两位评价者独立对纳入的研究进行资料提取,并使用Cochrane偏倚风险评估工具评估文献的方法学质量,利用RevMan5.3软件进行meta分析。结果:检索相关文献97篇,最终纳入13项研究,涉及1 189例患者。Meta分析结果显示,在临床总有效率方面,试验组临床疗效优于对照组[相对危险度(RR)=1.18,95%CI(1.13,1.24),P<0.000 01];在改善肺功能方面,试验组改善FEV1(L)[加权均数差(WMD)=0.48,95%CI(0.22,0.74),P=0.000 3]、FVC(L)[WMD=1.23,95%CI(0.5,1.96),P=0.001]、FEV1/FVC(%)[WMD=7.37,95%CI(5.91,8.84),P<0.000 01]和PEF[标准化均数差(SMD)=1.19,95%CI(0.82,1.56),P<0.000 01]优于对照组;在炎性因子指标改善方面,试验组改善IL-4[WMD=-12.13,95%CI(-16.36,-7.90),P<0.000 01]、IL-6[WMD=-29.55,95%CI(-40.71,-18.39),P<0.00001]、TNF-α[SMD=-2.73,95%CI(-3.57,-1.88),P<0.000 01]优于对照组;在改善动脉血气分析指标方面,试验组改善PaO2[WMD=8.97,95%CI(6.09,11.85),P<0.000 01]优于对照组;在不良事件发生率方面,对试验组、对照组不良事件发生频率进行分析,发现两组不良事件发生风险[RR=0.68,95%CI(0.39,1.18),P=0.17]差异无统计学意义。结论:寒喘祖帕颗粒治疗支气管哮喘具有较好的临床疗效,且不会增加不良事件发生率。